The treatment for addiction

 

(57) Abstract:

The invention relates to medicine. It is proposed to use mielopid for the treatment of drug addiction. The tool helps to overcome the craving for the drug and improves psycho-emotional condition of patients.

The invention relates to medicine, in particular to the means for the treatment of drug addiction.

The complex drugs in the treatment of drug addiction, which allows to reduce terms of relief of withdrawal symptoms. For this once a day intramuscularly complex medicines, including pentamin 1.0 ml of 5% analgin 3.0 ml of 50%, diphenhydramine 2.0 ml of 1% and Relanium 4,0-8,0 ml in Conjunction with drug therapy exercise suggestion influence, which form the patient's psychological setting on cessation of drug use, reducing or eliminating painful symptoms, intolerance of drug use and psychological setting to sleep in 6-12 hours (RU, patent N 2131245 And 61 To 31/13, 1999).

Know the use of a drug derived from the opium of alkaloid - morphine in the treatment of drug addiction. In the body of the patient is injected potentiated optionscom method from the initial substance habitual drug (RU, patent N 2104006, a 61 K 31/485, 1998).

Known medicinal product for relief of withdrawal syndrome in opiate-addiction - leupeptin (RU, patent N 2083204, a 61 K 31/485, 1997).

Know the use of apomorphine hydrochloride in combination with a solution of pilocarpine hydrochloride in the treatment of opium-martinich of drug addiction (SU, author's certificate N 1706624, 1992).

There is a method of treatment of drug abuse, including the introduction of atropine in a dose that causes coma in which the patient is 4 hours, and then remove it from this state, when this procedure is repeated at least 10-12 times, and in the first days of treatment daily, then every other day (RU, patent N 2129866 And 61 To 31/46, 1999).

It is known for the treatment of drug addiction and the treatment of this use. This tool contains synergistically active ingredients nonapeptide DSIP with the amino acid sequence Trp-Ala-Gly-Fsp-Ala-Ser-Gly-Glu and glycine. The drug is administered intranasally at a dose of 0.3-0.9 mg/day for 1-3 days (RU, patent N 2099078, a 61 K 38/08, 1997).

Known remedy for relief of withdrawal syndrome in opiate drug addiction, which offered a well-known inhibitor of p is Lenna of the invention is the expansion of the means for the treatment of addiction, improving the immunological status of patients with drug and increase the effectiveness of drug treatment craving for the drug.

To achieve the technical result as a treatment for drug use mielopid obtained by extraction of the culture of bone marrow cells in mammals, in addition to traditional therapy for relief of acute manifestations of heroin withdrawal and subsequent post-abstinent disorders.

It is known tool - mielopid obtained by extraction of the culture of bone marrow cells in mammals (instructions for use of mielopid approved by the Pharmacological Committee minzdravmedproma of the Russian Federation on March 17, 1994), used as a prophylactic and therapeutic agent in adults and children with transient and chronic immunodeficiency. And as a prophylactic agent to prevent the development of General and local infectious complications after surgery, traumatic brain injuries, fractures, burns, and other injuries. The drug is administered intramuscularly.

Mielopid first used as a treatment for addiction. Such application of p is obvious to an experienced specialist pharmacologist and suddenly the doctor-psychiatrist. Follows from well-known technical level, the ability of mielopid to have set aside immunomodulatory effect in combination with more early manifested the ability to overcome drug resistance and to improve the psycho-emotional condition of patients.

The claimed invention is as follows. The treatment of patients suffering from opium addiction, starting from the first days of abstinence syndrome by introducing them intramuscularly of mielopid at a dose of 3-5 mg a day, a total of five injections, in combination with usually carried out in such cases therapy, including neuroleptics, tranquilizers, antidepressants, and other symptoms.

Clinical and immunological study conducted in the clinic. A study in the dynamics of abstinence and post-abstinent periods immunobloting status. It was noted distinct immunodeficiency condition regarding virtually all populations of immune cells: micro - and macrophages, T-populations of lymphocytes, natural killer cells. Treatment mielopid held on 15 adolescents suffering from opium addiction. Mielopid allowed to achieve normalization of most pokazatel the treatment for the drug and associated with him, psychopathological disorders, such as affective disorders, insomniaque disorders, behavior disorders, leading to failure of the patient to continue treatment and relapse of the disease.

Analysis of the results of the drug has shown its effectiveness as a means of suppression of craving and related psychopathological disorders. In the group of patients treated with mielopid, craving for heroin was less than in the group receiving only conventional therapy. Significantly was neutralized affective disorders, rarely observed behavioral deviations. Patients better respond to psychopharmacological therapy and treatment required lower doses of drugs. Most importantly, there was an increase in time spent sick in narcological hospital because of a reduction in cases of refusal of treatment under the influence of the acute syndrome craving for the drug. In the group of patients not receiving mielopid, the average length of a hospital stay was $ 27,080,85 days, and patients who were appointed mielopid 35,450,78.

It is known that the immune system is correlated with the overall mental state. Reduction agunah of withdrawal syndrome and post-abstinent disorders (neuroleptics, tranquilizers, antidepressants) substantially able to exert a dampening effect on the patients and in particular on their intellectual sphere. The state drug utilization in conjunction with immunodeficiency caused by taking heroin, substantially complicates psychotherapeutic work with these patients, which is an important component of the anti-drug attitudes, skills optimal relapse behavior, significantly contributes to the strengthening of remission. In the group of patients (10 people) receiving mielopid, was significantly more frequently observed large accessibility to the psychotherapeutic process, increased productivity and emotional acclicense during group and individual psychotherapy, which ultimately leads to improving the quality of therapeutic remission.

Below are examples of the treatment of patients suffering from drug addiction.

Example 1. Patient A., 1984, p. the History N 768. Diagnosis: Heroin addiction. Enrolled in a Drug treatment hospital N 19 SC, Moscow, state intellego period of heroin withdrawal syndrome. Abuse heroin systematically 1 year, 5 months. CSEE malaise, pain in the calf muscles, lumbar region, low mood, craving for heroin, weakness. For relief of withdrawal syndrome patient was assigned to standard therapy consisting of neuroleptics, tranquilizers, antidepressants. On the first day of hospital stay the patient was assigned mielopid dose of 3 mg intramuscularly, every other day, a total of five injections. From the third day of applying mielopid there was a decrease in intensity of the main symptoms of heroin withdrawal syndrome: decreased intensity elegicheskij sensations, reduced fatigue, decreased level of depressive feelings and craving. Stage post-abstinent disorders flowed much easier. To a lesser extent was expressed pathological attraction to drugs, apathy, asthenia. Quickly degenerate associated with the syndrome of pathological urge affective disorders. The patient's behavior was ordered, he was actively involved in the psychotherapeutic process.

During dynamic studies of immunological parameters showed that the patient was admitted for treatment in moderate immunosuppression, manifested in sultate sharply reduced immunoregulatory index or the ratio T/TC. Depressed is also a system of phagocytes: macrophages (or neutrophils) and macrophages or monocytes). To the 21st day of treatment was normalized as the total number of leukocytes, and the individual shoots of the immune system: significant increase in the number of neutrophilic granulocytes, increased the percentage of T-helper cells has reached the upper limit of normal immunoregulatory index significantly increased antigen activation (CD 73) as in T-and b-lymphocytes, increased the percentage of NK-cells.

Immune activation is accompanied by a decrease in the activity of serum liver enzymes, elevated source that testifies to the development of pathological changes in tissues. Thus, the activity aspartaminotransferazy decreased with an 80.2 to 36.1 u/l, alanintransferzy with 70,2 up to 38.4 u/l

Discharged after 30 days of hospitalization.

The follow-up. Went to work, took supportive therapy, regularly attended psychotherapy sessions. During the whole period of psychoactive substances are not used.

Example 2. Patient 3., 1982 R. the history N 1017, was admitted for inpatient treatment in a Drug treatment hospital N 19 SC, Moscow with a diagnosis of hereinafater, not previously treated. Upon receipt complained of severe pains in the muscles of the legs, back, poor sleep, anxiety, irritability. To relieve this condition the patient was assigned to therapy with the use of analgesics, tranquilizers, neuroleptics. From the first day to the standard treatment regimen was added injection of mielopid dose of 3 mg intramuscularly, every day, in total, was administered to 5 injections. On the background of this therapy on the 4th day the patient was observed almost complete reduction of withdrawal disorders. In post-abstinent period in a shorter time was achieved normalization of background mood, recovery, sleep, decrease craving for the drug.

In the study of dynamic immunobloting status of the patient revealed a moderately severe immunosuppression during hospitalization, especially in the system of macrophages (neutrophilic granulocytes). By 21 day observed normalization of the number of neutrophilic granulocytes, increased the percentage of T-helper cells, immunoregulatory index at the top within the boundaries of age norms, T-and b-lymphocytes increased antigen activation (CD73), and also increased the percentage of NK-cells. In addition, normalized total number is about 44,8 u/l, alaninetransaminase with 94,4 to 36.6 u/l

On the 32nd day of treatment was discharged in good condition.

The follow-up. During the entire follow-up period (1 year) drugs are not used, according to the recommendations of the attending physician took maintenance treatment, willingly visited individual psychotherapy sessions.

As shown in clinical studies mielopid a drug for the treatment of drug addiction and eventually has an effect, overwhelming craving for the drug. Thus, the drug can be recommended for inclusion in the scheme of treatment of patients with heroin addiction.

The use of mielopid obtained by extraction of the culture of bone marrow cells in mammals, as a means for treatment of drug addiction.

 

Same patents:
The invention relates to medicine

The invention relates to medicine
The invention relates to medicine, namely to addiction
The invention relates to pharmacy and medicine and relates to a medicinal product for the treatment of patients with opiate addiction and their treatment
The invention relates to medicine
Neurotropic drug // 2156621
The invention relates to medicine and can be used for the correction of impaired immune homeostasis accompanied by changes psychosomatic functions and/or biological reactions, through a multifaceted impact on the integrative activity of the brain
The invention relates to medicine and can be used for treatment of drug addiction, alcoholism, Smoking, and various morbid attraction to the constant intake of toxic substances with the development of chronic intoxication

The invention relates to the field of veterinary medicine

The invention relates to medicine, namely to preparative biochemistry, pharmaceutical industry and biotechnology and relates to peptides having immunostimulatory activity, the method of their derivation, drug Splendida created on the basis of these peptides and its application

The invention relates to the field of medicine and is concerned with the obtaining medicines from animal waste
The invention relates to medicine, namely to traumatology, orthopedics

The invention relates to the field of medicine and is concerned with the obtaining medicines from animal waste
The invention relates to medicine, namely to Oncology, and for the treatment of patients with advanced tumors of the abdominal cavity
The immune method // 2131257
The invention relates to the field of therapeutic and preventive medicine and can be used to immunocorrective in the prevention and treatment of seasonal colds accompanied by a reduction in immunity

The invention relates to medicine, in particular for cell therapy and can be used for the treatment of diseases caused by disorders of the immune system, for example, diabetes

FIELD: medicine, surgery, transplantology.

SUBSTANCE: embryonic spleen should be sampled, washed in nutritive medium № 199 to be placed into fresh medium № 199 to obtain homogenate in teflon homogenizer followed by centrifuging; then one should isolate the upper, medium and inferior layers, suck off medium layer and the upper part of inferior layer; the cell mixture obtained should be diluted in nutritive medium № 199 to be then introduced by injections into mesentery of small intestine or rectus muscle of abdomen. The present innovation favors the activation of immune system in patients undergone splenectomic operation and in those in case of surgical immunodefficient state due to high functional and regenerating activity of transferred embryonic splenic cells.

EFFECT: higher efficiency of prophylaxis.

6 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves using mononuclear autologic marrow fraction containing 6-9x104 mesenchyma cells per 1 ml or autologic mesenchyma trunk cells. The cells are separated from brain bioptate in the amount of 106 cells/kg of patient body mass. The preparations are intracoronarily introduced in fractions at a rate of 3-5 ml/min into the right coronary artery. The introduction is also carried out in intra-arterial mode in jets or in drops.

EFFECT: higher survival rate and life quality of cardiologic patients.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing autologic mesenchyma trunk cells as a single intravenous drop dose or in the amount of 1 mln cells per 1 kg of patient body weight.

EFFECT: provided stable clinical remission.

FIELD: medicine, surgery.

SUBSTANCE: method involves every day covering a wound with an agent comprising of pig spleen homogenate and oxygenated with perfluorane taken in the following amounts: 100 g of pig spleen homogenate and 10 ml of oxygenated perfluorane. Invention promotes to accelerating sanitation of suppurative wounds due to activation of topical immunity and activation of regenerating processes. Invention can be used in treatment of suppurative wounds.

EFFECT: improved treatment method of wounds.

2 ex

Up!